These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 16687625)

  • 1. Safety and efficacy of a calcineurin inhibitor avoidance regimen in pediatric renal transplantation.
    Harmon W; Meyers K; Ingelfinger J; McDonald R; McIntosh M; Ho M; Spaneas L; Palmer JA; Hawk M; Geehan C; Tinckam K; Hancock WW; Sayegh MH
    J Am Soc Nephrol; 2006 Jun; 17(6):1735-45. PubMed ID: 16687625
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Conversion from calcineurin inhibitor to sirolimus in pediatric chronic allograft nephropathy.
    Falger JC; Mueller T; Arbeiter K; Boehm M; Regele H; Balzar E; Aufricht C
    Pediatr Transplant; 2006 Jun; 10(4):474-8. PubMed ID: 16712606
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sirolimus-based triple immunosupression with antithymocyte globulin induction in expanded criteria donor kidney transplantation.
    Uslu A; Nart A; Taşli FA; Postaci H; Aykas A; Doğan M; Sahin T
    Nephrology (Carlton); 2008 Feb; 13(1):80-6. PubMed ID: 18199109
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Steroid-free immunosuppression after renal transplantation-long-term experience from a single centre.
    El-Faramawi M; Rohr N; Jespersen B
    Nephrol Dial Transplant; 2006 Jul; 21(7):1966-73. PubMed ID: 16574678
    [TBL] [Abstract][Full Text] [Related]  

  • 5. No difference in degree of interstitial Sirius red-stained area in serial biopsies from area under concentration-over-time curves-guided cyclosporine versus tacrolimus-treated renal transplant recipients at one year.
    Rowshani AT; Scholten EM; Bemelman F; Eikmans M; Idu M; Roos-van Groningen MC; Surachno JS; Mallat MJ; Paul LC; de Fijter JW; Bajema IM; ten Berge I; Florquin S
    J Am Soc Nephrol; 2006 Jan; 17(1):305-12. PubMed ID: 16306168
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Untreated rejection in 6-month protocol biopsies is not associated with fibrosis in serial biopsies or with loss of graft function.
    Scholten EM; Rowshani AT; Cremers S; Bemelman FJ; Eikmans M; van Kan E; Mallat MJ; Florquin S; Surachno J; ten Berge IJ; Bajema IM; de Fijter JW
    J Am Soc Nephrol; 2006 Sep; 17(9):2622-32. PubMed ID: 16899517
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sirolimus in pediatric patients: results in the first 6 months post-renal transplant.
    Hymes LC; Warshaw BL
    Pediatr Transplant; 2005 Aug; 9(4):520-2. PubMed ID: 16048606
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preserving renal function in liver transplant recipients with rabbit anti-thymocyte globulin and delayed initiation of calcineurin inhibitors.
    Bajjoka I; Hsaiky L; Brown K; Abouljoud M
    Liver Transpl; 2008 Jan; 14(1):66-72. PubMed ID: 18161842
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Living related kidney transplantation without calcineurin inhibitors: initial experience in a Mexican center.
    Martinez-Mier G; Mendez-Lopez MT; Budar-Fernandez LF; Estrada-Oros J; Franco-Abaroa R; George-Micelli E; Rios-Martinez L; Mendez-Machado GF
    Transplantation; 2006 Dec; 82(11):1533-6. PubMed ID: 17164728
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial.
    Schena FP; Pascoe MD; Alberu J; del Carmen Rial M; Oberbauer R; Brennan DC; Campistol JM; Racusen L; Polinsky MS; Goldberg-Alberts R; Li H; Scarola J; Neylan JF;
    Transplantation; 2009 Jan; 87(2):233-42. PubMed ID: 19155978
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Avoidance of calcineurin inhibitors with use of proliferation signal inhibitors in de novo heart transplantation with renal failure.
    González-Vílchez F; de Prada JA; Exposito V; García-Camarero T; Fernández-Friera L; Llano M; Ruano J; Martín-Durán R
    J Heart Lung Transplant; 2008 Oct; 27(10):1135-41. PubMed ID: 18926406
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is acute rejection the key predictor for long-term outcomes after renal transplantation when comparing calcineurin inhibitors?
    Nashan B
    Transplant Rev (Orlando); 2009 Jan; 23(1):47-52. PubMed ID: 19027616
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Five-year follow-up after late conversion from calcineurin inhibitors to sirolimus in patients with chronic renal allograft dysfunction.
    Krüger B; Fischereder M; Jauch KW; Graeb C; Hoffmann U; Böger CA; Banas B; Obed A; Schlitt HJ; Krämer BK
    Transplant Proc; 2007 Mar; 39(2):518-21. PubMed ID: 17362772
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Conversion from calcineurin inhibitor to sirolimus in pediatric chronic allograft nephropathy.
    Falger JC; Mueller T; Arbeiter K; Boehm M; Regele H; Balzar E; Aufricht C
    Pediatr Transplant; 2006 Aug; 10(5):565-9. PubMed ID: 16856992
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multicenter trial of everolimus in pediatric renal transplant recipients: results at three year.
    Ettenger R; Hoyer PF; Grimm P; Webb N; Loirat C; Mahan JD; Mentser M; Niaudet P; Offner G; Vandamme-Lombaerts R; Hexham JM;
    Pediatr Transplant; 2008 Jun; 12(4):456-63. PubMed ID: 18466433
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Primary focal segmental glomerulosclerosis--long-term outcome after pediatric renal transplantation.
    Jungraithmayr TC; Bulla M; Dippell J; Greiner C; Griebel M; Leichter HE; Plank C; Tönshoff B; Weber LT; Zimmerhackl LB;
    Pediatr Transplant; 2005 Apr; 9(2):226-31. PubMed ID: 15787798
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stable graft function after reduction of calcineurin inhibitor dosage in paediatric kidney transplant patients.
    Plank C; Benz K; Amann K; Nüsken KD; Dittrich K; Rascher W; Sauerstein K; Stuppy A; Klare B; Dötsch J
    Nephrol Dial Transplant; 2006 Oct; 21(10):2930-7. PubMed ID: 16837512
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A prospective trial of a steroid-free/calcineurin inhibitor minimization regimen in human leukocyte antigen (HLA)-identical live donor renal transplantation.
    Walker JK; Alloway RR; Roy-Chaudhury P; Mogilishetty G; Cardi MA; Weimert NA; Rike AH; First MR; Woodle ES
    Transplantation; 2009 Feb; 87(3):408-14. PubMed ID: 19202447
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differences in proteinuria and graft function in de novo sirolimus-based vs. calcineurin inhibitor-based immunosuppression in live donor kidney transplantation.
    Stephany BR; Augustine JJ; Krishnamurthi V; Goldfarb DA; Flechner SM; Braun WE; Hricik DE; Dennis VW; Poggio ED
    Transplantation; 2006 Aug; 82(3):368-74. PubMed ID: 16906035
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pediatric kidney transplantation is safe and available for patients with urological anomalies as well as those with primary renal diseases.
    Morita K; Iwami D; Hotta K; Shimoda N; Miura M; Watarai Y; Hoshii S; Obikane K; Nakashima T; Sasaki S; Nonomura K
    Pediatr Transplant; 2009 Mar; 13(2):200-5. PubMed ID: 18662371
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.